Protalix BioTherapeutics
PLX
77 hedge funds and large institutions have $30.9M invested in Protalix BioTherapeutics in 2025 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 17 increasing their positions, 21 reducing their positions, and 3 closing their positions.
467% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 3
75% more capital invested
Capital invested by funds: $17.6M → $30.9M (+$13.3M)
22% more funds holding
Funds holding: 63 → 77 (+14)
2.51% more ownership
Funds ownership: 14.96% → 17.47% (+2.5%)
19% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 21
63% less call options, than puts
Call options by funds: $99K | Put options by funds: $269K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$4.2M |
| 2 |
BlackRock
New York
|
+$295K |
| 3 |
SWP
Stratos Wealth Partners
Beachwood,
Ohio
|
+$244K |
| 4 |
MSFS
Main Street Financial Solutions
Newtown,
Pennsylvania
|
+$210K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$187K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$637K |
| 2 |
Renaissance Technologies
New York
|
-$488K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$367K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$289K |
| 5 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
-$175K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SPIA
76
Steward Partners Investment Advisory
New York
| $56 | +$41 | +25 | New |
|
|
HIM
77
Hillsdale Investment Management
Toronto,
Ontario, Canada
| – | -$175K | -118,100 | Closed |
|
78
Two Sigma Investments
New York
| – | -$106K | -71,537 | Closed |
|
|
HIIFS
79
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
| – | -$40K | -26,000 | Closed |
|
80
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$265 | +163 | New |
|
PLX Hedge Fund Activity: Q3 2025 in Review
77 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q3 2025, worth a combined $30.9M — up 75% from $17.6M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new PLX positions and 3 closed out — a net gain of 14 holders — while 17 added to existing stakes and 21 trimmed.
The largest buyer was Opaleye Management, opening a new position worth an estimated $4.2M. The largest seller was Morgan Stanley, cutting an estimated $637K.
- 77 institutional investors held Protalix BioTherapeutics (PLX) as of Q3 2025, up from 63 in Q2 2025.
- Funds reported $30.9M of Protalix BioTherapeutics stock for Q3 2025, up 75% quarter-over-quarter.
- 17 funds opened new Protalix BioTherapeutics positions in Q3 2025 and 3 closed out, a net change of +14 holders.
- The largest Protalix BioTherapeutics buyer in Q3 2025 was Opaleye Management, an estimated $4.2M added.
- The largest Protalix BioTherapeutics seller in Q3 2025 was Morgan Stanley, an estimated $637K sold.
Based on aggregated 13F filings for Q3 2025.